Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Annals of the Rheumatic Diseases 72.12 (2013): S. 2039-2046.
- Schlagwort
-
-
Hautkrankheit
Dermatologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2013
- Urheber
-
Maurer, Britta
Distler, Alfiya
Dees, Clara
Khan, Korsa
Denton, Christopher P.
Abraham, David
Gay, Renate E.
Michel, Beat A.
Gay, Steffen
Distler, Jörg H. W.
Distler, Oliver
- URN
-
urn:nbn:de:bvb:29-opus4-81384
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maurer, Britta
- Distler, Alfiya
- Dees, Clara
- Khan, Korsa
- Denton, Christopher P.
- Abraham, David
- Gay, Renate E.
- Michel, Beat A.
- Gay, Steffen
- Distler, Jörg H. W.
- Distler, Oliver
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2013
Ähnliche Objekte (12)
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis
The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Editorial: Targeting bruton tyrosine kinase
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis
The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Editorial: Targeting bruton tyrosine kinase
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis
The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Tie2 as a novel key factor of microangiopathy in systemic sclerosis
Editorial: Targeting bruton tyrosine kinase
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis